Viscolin, a new chalcone from Viscum coloratum, inhibits human neutrophil superoxide anion and elastase release via a cAMP-dependent pathway

Free Radical Biology and Medicine

Volumn 41, Issue 9, 2006, Pages 1433-1441

  Hwang, Tsong Long ^a   Leu, Yann Lii ^a   Kao, Shu Hui ^a   Tang, Ming Chi ^a   Chang, Han Lin ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

cAMP; Elastase; Neutrophil; Superoxide; Viscolin; Viscum coloratum

Indexed keywords

ADENYLATE CYCLASE; CALCIUM ION; CHALCONE DERIVATIVE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ELASTASE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; SUPEROXIDE; UNCLASSIFIED DRUG; VISCOLIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM MOBILIZATION; CELL ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG ISOLATION; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; IC 50; INFLAMMATION; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VISCUM ALBUM; VISCUM COLORATUM;

BIPHENYL COMPOUNDS; CALCIUM; CHEMOTAXIS, LEUKOCYTE; CYCLIC AMP; CYTOSOL; HUMANS; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PANCREATIC ELASTASE; PROPANE; SIGNAL TRANSDUCTION; SUPEROXIDES; VISCUM;

SPRING VIREMIA OF CARP VIRUS; VISCUM;

EID: 33749049578     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2006.08.001     Document Type: Article

References (36)

1. Malech H.L., and Gallin J.I. Current concepts: immunology. Neutrophils in human diseases. N. Engl. J. Med. 317 (1987) 687-694
2. Witko-Sarsat V., Rieu P., Descamps-Latscha B., Lesavre P., and Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest. 80 (2000) 617-653
3. Okajima K., Harada N., and Uchiba M. Ranitidine reduces ischemia/reperfusion-induced liver injury in rats by inhibiting neutrophil activation. J. Pharmacol. Exp. Ther. 301 (2002) 1157-1165
4. Ennis M. Neutrophils in asthma pathophysiology. Curr. Allergy Asthma Rep. 3 (2003) 159-165
5. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc. Res. 61 (2004) 481-497
6. Borregaard N. The human neutrophil. Function and dysfunction. Eur. J. Haematol. 41 (1998) 401-413
7. Roos D., van Bruggen R., and Meischl C. Oxidative killing of microbes by neutrophils. Microbes. Infect. 5 (2003) 1307-1315
8. Winslow L.C., and Kroll D.J. Herbs as medicines. Arch. Intern. Med. 158 (1998) 2192-2199
9. Bielory L., and Lupoli K. Herbal interventions in asthma and allergy. J. Asthma 36 (1999) 1-65
10. Coffey R.G. Effects of cyclic nucleotides on granulocytes. Immunol. Ser. 57 (1992) 301-338
11. Flamand N., Surette M.E., Picard S., Bourgoin S., and Borgeat P. Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol. Pharmacol. 62 (2002) 250-256
12. O'Dowd Y.M., El-Benna J., Perianin A., and Newsholme P. Inhibition of formyl-methionyl-leucyl-phenylalanine-stimulated respiratory burst in human neutrophils by adrenaline: inhibition of phospholipase A2 activity but not p47phox phosphorylation and translocation. Biochem. Pharmacol. 67 (2004) 183-190
13. Lin P., Welch E.J., Gao X.P., Malik A.B., and Ye R.D. Lysophosphatidylcholine modulates neutrophil oxidant production through elevation of cyclic AMP. J. Immunol. 174 (2005) 2981-2989
14. Flamand N., Boudreault S., Picard S., Austin M., Surette M.E., Plante H., Krump E., Vallee M.J., Gilbert C., Naccache P., Laviolette M., and Borgeat P. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Am. J. Respir. Crit. Care Med. 161 (2000) S88-S94
15. Harada N., Okajima K., Murakami K., Usune S., Sato C., Ohshima K., and Katsuragi T. Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J. Pharmacol. Exp. Ther. 294 (2000) 1034-1042
16. Cadieux J.S., Leclerc P., St-Onge M., Dussault A.A., Laflamme C., Picard S., Ledent C., Borgeat P., and Pouliot M. Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J. Cell Sci. 118 (2005) 1437-1447
17. Miotla J.M., Teixeira M.M., and Hellewell P.G. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am. J. Respir. Cell Mol. Biol. 18 (1998) 411-420
18. Compton C.H., Gubb J., Nieman R., Edelson J., Amit O., Bakst A., Ayres J.G., Creemers J.P., Schultze-Werninghaus G., Brambilla C., Barnes N.C., and International Study Group. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358 (2001) 265-270
19. Gamble E., Grootendorst D.C., Brightling C.E., Troy S., Qiu Y., Zhu J., Parker D., Matin D., Majumdar S., Vignola A.M., Kroegel C., Morell F., Hansel T.T., Rennard S.I., Compton C., Amit O., Tat T., Edelson J., Pavord I.D., Rabe K.F., Barnes N.C., and Jeffery P.K. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 168 (2003) 976-982
20. Tintinger G., Steel H.C., and Anderson R. Taming the neutrophil: calcium clearance and influx mechanisms as novel targets for pharmacological control. Clin. Exp. Immunol. 141 (2005) 191-200
21. Boyum A., Lovhaug D., Tresland L., and Nordlie E.M. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand. J. Immunol. 34 (1991) 697-712
22. Babior B.M., Kipnes R.S., and Curnutte J.T. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J. Clin. Invest. 52 (1973) 741-744
23. Sklar L.A., McNeil V.M., Jesaitis A.J., Painter R.G., and Cochrane C.G. A continuous, spectroscopic analysis of the kinetics of elastase secretion by neutrophils. The dependence of secretion upon receptor occupancy. J. Biol. Chem. 257 (1982) 5471-5475
24. Coles B., Bloodsworth A., Clark S.R., Lewis M.J., Cross A.R., Freeman B.A., and O'Donnell V.B. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circ. Res. 91 (2002) 375-381
25. Anderson R., Goolam Mahomed A., Theron A.J., Ramafi G., and Feldman C. Effect of rolipram and dibutyryl cyclic AMP on resequestration of cytosolic calcium in FMLP-activated human neutrophils. Br. J. Pharmacol. 124 (1998) 547-555
26. Hwang T.L., Hung H.W., Kao S.H., Teng C.M., Wu C.C., and Cheng S.J. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol. Pharmacol. 64 (2003) 1419-1427
27. Berridge M.J. Inositol trisphosphate and calcium signalling. Nature 361 (1993) 315-325
28. Tintinger G.R., Theron A.J., Anderson R., and Ker J.A. The anti-inflammatory interactions of epinephrine with human neutrophils in vitro are achieved by cyclic AMP-mediated accelerated resequestration of cytosolic calcium. Biochem. Pharmacol. 61 (2001) 1319-1328
29. Giner-Larza E.M., Manez S., Recio M.C., Giner R.M., Prieto J.M., Cerda-Nicolas M., and Rios J.L. Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity. Eur. J. Pharmacol. 428 (2001) 137-143
30. Schudt C., Winder S., Forderkunz S., Hatzelmann A., and Ullrich V. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn-Schmiedebergs Arch. Pharmacol. 344 (1991) 682-690
31. VanUffelen B.E., de Koster B.M., and Elferink J.G. Interaction of cyclic GMP and cyclic AMP during neutrophil migration: involvement of phosphodiesterase type III. Biochem. Pharmacol. 56 (1998) 1061-1063
32. Smith S.J., Brookes-Fazakerley S., Donnelly L.E., Barnes P.J., Barnette M.S., and Giembycz M.A. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am. J. Physiol. Lung Cell Mol. Physiol. 284 (2003) L279-L289
33. Ariga M., Neitzert B., Nakae S., Mottin G., Bertrand C., Pruniaux M.P., Jin S.L., and Conti M. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J. Immunol. 173 (2004) 7531-7538
34. Staubach K.H., Schroder J., Stuber F., Gehrke K., Traumann E., and Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch. Surg. 133 (1998) 94-100
35. Lauterbach R. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial. Crit. Care Med. 27 (1999) 807-814
36. Rocco P.R., Momesso D.P., Figueira R.C., Ferreira H.C., Cadete R.A., Legora-Machado A., Koatz V.L., Lima L.M., Barreiro E.J., and Zin W.A. Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury. Eur. Respir. J. 22 (2003) 20-27